Literature DB >> 6124268

Comparison between atenolol and nadolol in essential hypertension at rest and on exercise.

R G Wilcox, J R Hampton.   

Abstract

1 The effects of 4 week treatment periods of once-daily atenolol 100 mg, nadolol 80 mg, nadolol 160 mg and placebo on resting and exercise heart rate and blood pressure were compared in a single-blind crossover trial in fifteen patients with essential hypertension. 2 Both atenolol and nadolol, irrespective of dose, reduced resting and exercise blood pressures to the same extent. 3 Nadolol caused a greater bradycardia both at rest and during exercise than did atenolol, thereby effecting a greater reduction in double-product. 4 During progressive treadmill exercise neither atenolol nor nadolol prevented a linear increase in heart rate and blood pressure which were parallel to, but at a lower level than, that produced by placebo. 5 In each individual patient the magnitude of the hypotensive effect produced by one drug was similar to that produced by the other. 6 All the treatment periods resulted in the same linear increase in the patients' perceived exertion scores during exercise despite marked differences in haemodynamic responses evoked by the beta-adrenoceptor blockers compared with placebo. 7 Neither atenolol or nadolol produced any significant change in peak expiratory flow rate compared with placebo.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6124268      PMCID: PMC1402028          DOI: 10.1111/j.1365-2125.1982.tb01876.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  25 in total

1.  Plasma concentrations and the time-course of beta blockade due to propranolol.

Authors:  D G McDevitt; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-12       Impact factor: 6.875

2.  Pharmacology of nadolol (SQ 11725), a beta-adrenergic antagonist lacking direct myocardial depression.

Authors:  R J Lee; D B Evans; S H Baky; R J Laffan
Journal:  Eur J Pharmacol       Date:  1975 Sep-Oct       Impact factor: 4.432

3.  Anti-arrhythmic action of nadolol, a beta-adrenergic receptor blocking agent.

Authors:  D B Evans; M T Peschka; R J Lee; R J Laffan
Journal:  Eur J Pharmacol       Date:  1976-01       Impact factor: 4.432

4.  Relationship between blood level of atenolol and pharmacologic effect.

Authors:  A Amery; J F De Plaen; P Lijnen; J McAinsh; T Reybrouck
Journal:  Clin Pharmacol Ther       Date:  1977-06       Impact factor: 6.875

Review 5.  Individualization of propranolol therapy.

Authors:  D G Shand
Journal:  Med Clin North Am       Date:  1974-09       Impact factor: 5.456

6.  Exercise testing of patients with coronary heart disease. Principles and normal standards for evaluation.

Authors:  R A Bruce
Journal:  Ann Clin Res       Date:  1971-12

7.  The effect on blood pressure of beta-adrenoceptor blocking drugs administered once daily and their duration of action when therapy is ceased.

Authors:  M Wilson; G Morgan; T Morgan
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

8.  Plasma levels and effects of metoprolol on blood pressure and heart rate in hypertensive patients after an acute dose and between two doses during long-term treatment.

Authors:  C Bengtsson; G Johnsson; C G Regårdh
Journal:  Clin Pharmacol Ther       Date:  1975-04       Impact factor: 6.875

9.  Once-daily dosing with Atenolol in patients with mild or moderate hypertension.

Authors:  A P Douglas-Jones; J M Cruickshank
Journal:  Br Med J       Date:  1976-04-24

10.  Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker.

Authors:  H C Brown; S G Carruthers; G D Johnston; J G Kelly; J McAinsh; D G McDevitt; R G Shanks
Journal:  Clin Pharmacol Ther       Date:  1976-11       Impact factor: 6.875

View more
  2 in total

1.  A comparison of the effects of flosequinan, a new vasodilator, and propranolol on sub-maximal exercise in healthy volunteers.

Authors:  H M Lewis; M J Kendall; S R Smith; J R Bratty
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

Review 2.  Pharmacokinetics of long acting propranolol. Implications for therapeutic use.

Authors:  G S Nace; A J Wood
Journal:  Clin Pharmacokinet       Date:  1987-07       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.